WILLIAM CONKLING
CIK 1852018 · Chief Commercial Officer · last filed 2026-06-11
WILLIAM CONKLING is a Chief Commercial Officer who has filed 28 SEC Form 4 insider transactions across 5 companies since 2021. The most recent filing shows the insider was granted $37.5K of IDT on Jun 11, 2026. Current disclosed insider exposure totals $1.4M across reported positions. 17 SEC filings were submitted jointly with Rafael Holdings, Inc.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$1.38M
5
28
$0
Filer Profile
345 PARK AVENUE SOUTH, 3RD FLOOR
NEW YORK, NY 10010
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| IDT | Director | 673 | $67.87 | $45.7K | $0 | 1 | 2026-06-11 |
| TARA | Chief Commercial Officer | 69,992 | $3.54 | $247.8K | $0 | 3 | 2026-06-03 |
| Rafael Holdings, Inc. (RFL.WS) Delisted | Chief Executive Officer | 564,455 | $0.01 | $8.0K | $0 | 1 | 2025-04-24 |
| RFL | Chief Executive Officer | 537,001 | $2.02 | $1.08M | $0 | 15 | 2025-03-25 |
| Cyclo Therapeutics, Inc. (CYTHW) Delisted | Director | 77,884 | $0.03 | $2.5K | $0 | 8 | 2025-03-03 |
Recent Filings
28 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-11 | IDT | Grant (A) | +673 | $37.5K | EDGAR |
| 2026-06-03 | TARA | Tax (F) | −6,008 | -$26.1K | EDGAR |
| 2026-01-21 | TARA | Grant (A) | +26,000 | $0 | EDGAR |
| 2025-06-04 | TARA | Grant (A) | +50,000 | $0 | EDGAR |
| 2025-04-24 | Rafael Holdings, Inc. (RFL.WS) Delisted | Grant (A) | +27,454 | $0 | EDGAR |
| 2025-03-25 | RFL | Tax (F) | −14,814 | -$28.6K | EDGAR |
| 2025-03-03 | Cyclo Therapeutics, Inc. (CYTHW) Delisted | Grant (A) | +27,654 | $0 | EDGAR |
| 2025-01-15 | RFL | Grant (A) | +60,000 | $117.2K | EDGAR |
| 2024-12-23 | RFL | Tax (F) | −12,807 | -$23.5K | EDGAR |
| 2024-11-18 | Cyclo Therapeutics, Inc. (CYTHW) Delisted | Grant (A) | +16,660 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.